Product
131I-MIBG
2 clinical trials
7 indications
Indication
NeuroblastomaIndication
Neuroectodermal TumorsIndication
CancerIndication
Neuroendocrine TumorIndication
malignantIndication
Neuroendocrine Tumor (Gastrointestinal)Indication
Hormone SecretingClinical trial
A Phase II, Open Label, Two-Arm Study of Therapeutic Iobenguane (131I) as Single Agent or in Combination With Vorinostat for Recurrent or Progressive High- Risk Neuroblastoma Subjects (OPTIMUM TRIAL)Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
Phase 1 Trial Using 131I MIBG and 90Y DOTATOC in a Dosimetrically Determined Optimal Combination for Therapy of Selected Patients With Midgut Neuroendocrine Tumors.Status: Active (not recruiting), Estimated PCD: 2025-12-01